102 related articles for article (PubMed ID: 35912837)
1. Etiological relationship between lipid metabolism and endometrial carcinoma.
Li W; Xu Y; Zeng X; Tan J; Wang Y; Wu H; Li M; Yi C
Lipids Health Dis; 2023 Aug; 22(1):116. PubMed ID: 37537560
[TBL] [Abstract][Full Text] [Related]
2. The role and participation of immune cells in the endometrial tumor microenvironment.
Dey DK; Krause D; Rai R; Choudhary S; Dockery LE; Chandra V
Pharmacol Ther; 2023 Nov; 251():108526. PubMed ID: 37690483
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive analysis of immunotherapy in advanced endometrial cancer (Review).
Wang L; Liu L; Huo D; Zhang Y
Oncol Lett; 2024 Feb; 27(2):77. PubMed ID: 38192679
[TBL] [Abstract][Full Text] [Related]
4. Features of the immunosuppressive tumor microenvironment in endometrial cancer based on molecular subtype.
Zhang C; Wang M; Wu Y
Front Oncol; 2023; 13():1278863. PubMed ID: 37927462
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances in Endometrial Cancer Prevention, Early Diagnosis and Treatment.
Baker-Rand H; Kitson SJ
Cancers (Basel); 2024 Mar; 16(5):. PubMed ID: 38473385
[TBL] [Abstract][Full Text] [Related]
6. Current Prognostic and Predictive Biomarkers for Endometrial Cancer in Clinical Practice: Recommendations/Proposal from the Italian Study Group.
Zannoni GF; Bragantini E; Castiglione F; Fassan M; Troncone G; Inzani F; Pesci A; Santoro A; Fraggetta F
Front Oncol; 2022; 12():805613. PubMed ID: 35463299
[TBL] [Abstract][Full Text] [Related]
7. Current Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial Cancer.
Gordhandas S; Zammarrelli WA; Rios-Doria EV; Green AK; Makker V
J Natl Compr Canc Netw; 2023 Feb; 21(2):217-226. PubMed ID: 36791759
[TBL] [Abstract][Full Text] [Related]
8. Advanced and recurrent endometrial cancer: State of the art and future perspectives.
Tronconi F; Nero C; Giudice E; Salutari V; Musacchio L; Ricci C; Carbone MV; Ghizzoni V; Perri MT; Camarda F; Gentile M; Berardi R; Scambia G; Lorusso D
Crit Rev Oncol Hematol; 2022 Dec; 180():103851. PubMed ID: 36257537
[TBL] [Abstract][Full Text] [Related]
9. Targeted Treatment of Advanced Endometrial Cancer: Focus on Pembrolizumab.
El-Ghazzi N; Durando X; Giro A; Herrmann T
Onco Targets Ther; 2023; 16():359-369. PubMed ID: 37288137
[TBL] [Abstract][Full Text] [Related]
10. Two pathogenetic types of endometrial carcinoma.
Bokhman JV
Gynecol Oncol; 1983 Feb; 15(1):10-7. PubMed ID: 6822361
[TBL] [Abstract][Full Text] [Related]
11. Understanding Characteristics, Treatment Patterns, and Clinical Outcomes for Individuals with Advanced or Recurrent Endometrial Cancer in Alberta, Canada: A Retrospective, Population-Based Cohort Study.
Martins D; O'Sullivan DE; Boyne DJ; Cheung WY; Allonby O; Habash M; Brenner DR; Riemer J; McGee J
Curr Oncol; 2023 Feb; 30(2):2277-2289. PubMed ID: 36826137
[TBL] [Abstract][Full Text] [Related]
12. Recent progress in the use of pharmacotherapy for endometrial cancer.
Giudice E; Salutari V; Ricci C; Nero C; Carbone MV; Musacchio L; Ghizzoni V; Perri MT; Camarda F; Tronconi F; Lorusso D; Scambia G
Expert Opin Pharmacother; 2023 Jan; 24(1):83-94. PubMed ID: 35912837
[TBL] [Abstract][Full Text] [Related]
13. New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere.
Bruchim I; Capasso I; Polonsky A; Meisel S; Salutari V; Werner H; Lorusso D; Scambia G; Fanfani F
Expert Opin Ther Targets; 2024; 28(1-2):29-43. PubMed ID: 38327111
[TBL] [Abstract][Full Text] [Related]
14. High risk endometrial cancer: Clues towards a revision of the therapeutic paradigm.
Bendifallah S; Ilenko A; Daraï E
J Gynecol Obstet Hum Reprod; 2019 Dec; 48(10):863-871. PubMed ID: 31176047
[TBL] [Abstract][Full Text] [Related]
15. Systemic therapy for the treatment of endometrial cancer.
Neri M; Peiretti M; Melis GB; Piras B; Vallerino V; Paoletti AM; Madeddu C; Scartozzi M; Mais V
Expert Opin Pharmacother; 2019 Nov; 20(16):2019-2032. PubMed ID: 31451034
[No Abstract] [Full Text] [Related]
16. Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors.
Wortman BG; Nout RA; Bosse T; Creutzberg CL
Curr Oncol Rep; 2019 Jul; 21(9):83. PubMed ID: 31367798
[TBL] [Abstract][Full Text] [Related]
17. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.
León-Castillo A; de Boer SM; Powell ME; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Singh N; Pollock PM; Bessette P; Fyles A; Haie-Meder C; Smit VTHBM; Edmondson RJ; Putter H; Kitchener HC; Crosbie EJ; de Bruyn M; Nout RA; Horeweg N; Creutzberg CL; Bosse T;
J Clin Oncol; 2020 Oct; 38(29):3388-3397. PubMed ID: 32749941
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
